Literature DB >> 6519167

Pharmacokinetics of methotrexate in erythrocytes in psoriasis.

J Hendel, A Nyfors.   

Abstract

The intraerythrocytic levels of folate and methotrexate were measured in 25 patients on long-term methotrexate therapy for recalcitrant psoriasis. The mean steady state concentration of methotrexate in erythrocytes was 85 nmol/l and the mean erythrocyte folate concentration was 729 nmol/l. A linear correlation was not observed between these parameters, but the greatest methotrexate accumulation was found in cells at the lower end of the erythrocyte folate concentration range. In 5 patients started on methotrexate therapy the erythrocyte concentrations of methotrexate and folate were followed over 6 months. 3-4 days after the first dose, methotrexate had been accumulated against a concentration gradient in the erythrocytes. The methotrexate concentration increased steadily until the steady state level was reached after 4-6 weeks. The steady state level was maintained during the 6 month observation period. The erythrocyte folate concentration did not change during this period. The data suggest that methotrexate polyglutamate synthesis within the circulating erythrocyte is a major cause of methotrexate accumulation in these cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519167     DOI: 10.1007/bf00556900

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Stoichiometric inhibition of mammalian dihydrofolate reductase by the gamma-glutamyl metabolite of methotrexiate, 4-amino-4-deoxy-N-10-methylpteroylglutamyl-gamma-glutamate.

Authors:  S A Jacobs; R H Adamson; B A Chabner; C J Derr; D C Johns
Journal:  Biochem Biophys Res Commun       Date:  1975-04-07       Impact factor: 3.575

2.  Determination of erythrocyte folate by competitive protein binding assay preceded by extraction.

Authors:  E Mortensen
Journal:  Clin Chem       Date:  1976-07       Impact factor: 8.327

3.  7,8-Dihydropteroyl oligo-gamma-L-glutamates: synthesis and kinetic studies with purified dihydrofolate reductase from mammalian sources.

Authors:  J K Coward; K N Parameswaran; A R Cashmore; J R Bertino
Journal:  Biochemistry       Date:  1974-09-10       Impact factor: 3.162

Review 4.  Methotrexate therapy of psoriasis. Effect and side effects with particular reference to hepatic changes. A survey.

Authors:  A Nyfors
Journal:  Dan Med Bull       Date:  1980-04

5.  Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment.

Authors:  H Zachariae; K Kragballe; H Søgaard
Journal:  Br J Dermatol       Date:  1980-04       Impact factor: 9.302

6.  5-methyl-5,6,7,8-tetrahydropteroyl oligo-gamma-L-glutamates: synthesis and kinetic studies with methionine synthetase from bovine brain.

Authors:  J K Coward; P L Chello; A R Cashmore; K N Parameswaran; L M DeAngelis; J R Bertino
Journal:  Biochemistry       Date:  1975-04-08       Impact factor: 3.162

7.  Synthesis of methotrexate polyglutamates by bone marrow cells from patients with leukemia and lymphoma.

Authors:  A Witte; V M Whitehead; D S Rosenblatt; M J Vuchich
Journal:  Dev Pharmacol Ther       Date:  1980

8.  Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug.

Authors:  B A Kamen; P A Nylen; B M Camitta; J R Bertino
Journal:  Br J Haematol       Date:  1981-11       Impact factor: 6.998

9.  Tissue-specific synthesis of methotrexate polyglutamates in the rat.

Authors:  V M Whitehead; M M Perrault; S Stelcner
Journal:  Cancer Res       Date:  1975-11       Impact factor: 12.701

10.  Pharmacokinetics of erythrocyte methotrexate after high-dose methotrexate.

Authors:  A Schalhorn; H Sauer; W Wilmanns; G Stupp-Poutot
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

View more
  10 in total

1.  Folate depletion and increased glutamation in juvenile idiopathic arthritis patients treated with methotrexate.

Authors:  Ryan S Funk; Leon van Haandel; J Steven Leeder; Mara L Becker
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

Review 2.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

3.  Methotrexate in erythrocytes of patients with psoriasis.

Authors:  H Schrøder; E K Foged
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Methotrexate in neutrophils in children with acute lymphoblastic leukemia.

Authors:  H Schrøder
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Methotrexate kinetics in myeloid bone marrow cells and peripheral neutrophils.

Authors:  H Schrøder
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Methotrexate pharmacokinetics in age-fractionated erythrocytes.

Authors:  H Schrøder
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

7.  In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes.

Authors:  H Schrøder; K Fogh; T Herlin
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia.

Authors:  H Schrøder; K Fogh
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Pharmacokinetics of erythrocyte methotrexate in children with acute lymphoblastic leukemia during maintenance treatment.

Authors:  H Schrøder; N Clausen; E Ostergaard; T Pressler
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

10.  Association of NUDT15*3 and FPGS 2572C>T Variants with the Risk of Early Hematologic Toxicity During 6-MP and Low-Dose Methotrexate-Based Maintenance Therapy in Indian Patients with Acute Lymphoblastic Leukemia.

Authors:  Sunitha Kodidela; Patchava Dorababu; Dimpal N Thakkar; Biswajit Dubashi; Rajan Sundaram; Niveditha Muralidharan; Ravi Prasad Nidanapu; Anil Aribandi; Suresh Chandra Pradhan; Chakradhara Rao Satyanarayana Uppugunduri
Journal:  Genes (Basel)       Date:  2020-05-28       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.